Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies. / Su, Yutian; Lv, Mengdi; Huang, Zheng; An, Nannan; Chen, Yi; Wang, Haoru; Li, Zhengtu; Wu, Shishan; Ye, Feng; Shen, Jian; Li, Ao.

In: Journal of Controlled Release, Vol. 367, 2024, p. 557-571.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Su, Y, Lv, M, Huang, Z, An, N, Chen, Y, Wang, H, Li, Z, Wu, S, Ye, F, Shen, J & Li, A 2024, 'Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies', Journal of Controlled Release, vol. 367, pp. 557-571. https://doi.org/10.1016/j.jconrel.2024.01.066

APA

Su, Y., Lv, M., Huang, Z., An, N., Chen, Y., Wang, H., Li, Z., Wu, S., Ye, F., Shen, J., & Li, A. (2024). Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies. Journal of Controlled Release, 367, 557-571. https://doi.org/10.1016/j.jconrel.2024.01.066

Vancouver

Su Y, Lv M, Huang Z, An N, Chen Y, Wang H et al. Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies. Journal of Controlled Release. 2024;367:557-571. https://doi.org/10.1016/j.jconrel.2024.01.066

Author

Su, Yutian ; Lv, Mengdi ; Huang, Zheng ; An, Nannan ; Chen, Yi ; Wang, Haoru ; Li, Zhengtu ; Wu, Shishan ; Ye, Feng ; Shen, Jian ; Li, Ao. / Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies. In: Journal of Controlled Release. 2024 ; Vol. 367. pp. 557-571.

Bibtex

@article{cabdd6f3bf8849f4a1f28756c4bb6b51,
title = "Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies",
abstract = "Pursuing biodegradable nanozymes capable of equipping structure-activity relationship provides new perspectives for tumor-specific therapy. A rapidly degradable nanozymes can address biosecurity concerns. However, it may also reduce the functional stability required for sustaining therapeutic activity. Herein, the defect engineering strategy is employed to fabricate Pt-doping MoOx (PMO) redox nanozymes with rapidly degradable characteristics, and then the PLGA-assembled PMO (PLGA@PMO) by microfluidics chip can settle the conflict between sustaining therapeutic activity and rapid degradability. Density functional theory describes that Pt-doping enables PMO nanozymes to exhibit an excellent multienzyme-mimicking catalytic activity originating from synergistic catalysis center construction with the interaction of Pt substitution and oxygen vacancy defects. The peroxidase- (POD), oxidase- (OXD), glutathione peroxidase- (GSH-Px), and catalase- (CAT) mimicking activities can induce robust ROS output and endogenous glutathione depletion under tumor microenvironment (TME) response, thereby causing ferroptosis in tumor cells by the accumulation of lipid peroxide and inactivation of glutathione peroxidase 4. Due to the activated surface plasmon resonance effect, the PMO nanozymes can cause hyperthermia-induced apoptosis through 1064 nm laser irradiation, and augment multienzyme-mimicking catalytic activity. This work represents a potential biological application for the development of therapeutic strategy for dual-channel death via hyperthermia-augmented enzyme-mimicking nanocatalytic therapy.",
keywords = "Biodegradability, Ferroptosis, Multienzyme-mimicking catalytic activity, Nanozymes, Sustaining therapeutic activity",
author = "Yutian Su and Mengdi Lv and Zheng Huang and Nannan An and Yi Chen and Haoru Wang and Zhengtu Li and Shishan Wu and Feng Ye and Jian Shen and Ao Li",
note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",
year = "2024",
doi = "10.1016/j.jconrel.2024.01.066",
language = "English",
volume = "367",
pages = "557--571",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies

AU - Su, Yutian

AU - Lv, Mengdi

AU - Huang, Zheng

AU - An, Nannan

AU - Chen, Yi

AU - Wang, Haoru

AU - Li, Zhengtu

AU - Wu, Shishan

AU - Ye, Feng

AU - Shen, Jian

AU - Li, Ao

N1 - Publisher Copyright: © 2024 Elsevier B.V.

PY - 2024

Y1 - 2024

N2 - Pursuing biodegradable nanozymes capable of equipping structure-activity relationship provides new perspectives for tumor-specific therapy. A rapidly degradable nanozymes can address biosecurity concerns. However, it may also reduce the functional stability required for sustaining therapeutic activity. Herein, the defect engineering strategy is employed to fabricate Pt-doping MoOx (PMO) redox nanozymes with rapidly degradable characteristics, and then the PLGA-assembled PMO (PLGA@PMO) by microfluidics chip can settle the conflict between sustaining therapeutic activity and rapid degradability. Density functional theory describes that Pt-doping enables PMO nanozymes to exhibit an excellent multienzyme-mimicking catalytic activity originating from synergistic catalysis center construction with the interaction of Pt substitution and oxygen vacancy defects. The peroxidase- (POD), oxidase- (OXD), glutathione peroxidase- (GSH-Px), and catalase- (CAT) mimicking activities can induce robust ROS output and endogenous glutathione depletion under tumor microenvironment (TME) response, thereby causing ferroptosis in tumor cells by the accumulation of lipid peroxide and inactivation of glutathione peroxidase 4. Due to the activated surface plasmon resonance effect, the PMO nanozymes can cause hyperthermia-induced apoptosis through 1064 nm laser irradiation, and augment multienzyme-mimicking catalytic activity. This work represents a potential biological application for the development of therapeutic strategy for dual-channel death via hyperthermia-augmented enzyme-mimicking nanocatalytic therapy.

AB - Pursuing biodegradable nanozymes capable of equipping structure-activity relationship provides new perspectives for tumor-specific therapy. A rapidly degradable nanozymes can address biosecurity concerns. However, it may also reduce the functional stability required for sustaining therapeutic activity. Herein, the defect engineering strategy is employed to fabricate Pt-doping MoOx (PMO) redox nanozymes with rapidly degradable characteristics, and then the PLGA-assembled PMO (PLGA@PMO) by microfluidics chip can settle the conflict between sustaining therapeutic activity and rapid degradability. Density functional theory describes that Pt-doping enables PMO nanozymes to exhibit an excellent multienzyme-mimicking catalytic activity originating from synergistic catalysis center construction with the interaction of Pt substitution and oxygen vacancy defects. The peroxidase- (POD), oxidase- (OXD), glutathione peroxidase- (GSH-Px), and catalase- (CAT) mimicking activities can induce robust ROS output and endogenous glutathione depletion under tumor microenvironment (TME) response, thereby causing ferroptosis in tumor cells by the accumulation of lipid peroxide and inactivation of glutathione peroxidase 4. Due to the activated surface plasmon resonance effect, the PMO nanozymes can cause hyperthermia-induced apoptosis through 1064 nm laser irradiation, and augment multienzyme-mimicking catalytic activity. This work represents a potential biological application for the development of therapeutic strategy for dual-channel death via hyperthermia-augmented enzyme-mimicking nanocatalytic therapy.

KW - Biodegradability

KW - Ferroptosis

KW - Multienzyme-mimicking catalytic activity

KW - Nanozymes

KW - Sustaining therapeutic activity

U2 - 10.1016/j.jconrel.2024.01.066

DO - 10.1016/j.jconrel.2024.01.066

M3 - Journal article

C2 - 38301929

AN - SCOPUS:85184005640

VL - 367

SP - 557

EP - 571

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -

ID: 382494847